Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer (PEARL-C1)

Single-group Phase II feasibility and safety study of a single 25 mg oral psilocybin dose delivered within PEARL psychotherapy (preparatory sessions, dosing session, and integration) for caregivers of patients with advanced cancer.

Outcomes include feasibility, acceptability, psychological measures (depression, anxiety, anticipatory grief, quality of life), and safety assessments including vital signs and adverse events; participants must meet screening laboratory and contraceptive requirements.